Dutch State Announces the Sale of Intravacc B.V. (The Netherlands)
The Hague, The Netherlands, 3 May 2023 – The State of the Netherlands, the Dutch Ministry of Health, Welfare and Sport today announces its intentions to sell 100% of the issued and outstanding shares in the capital of Intravacc B.V. through a controlled auction process.
Intravacc, located at Utrecht Science Park Bilthoven in the Netherlands, is an established independent contract development and manufacturing organization for infectious diseases and therapeutic vaccines. As a CDMO with many years of experience in the development and optimization of vaccines and vaccine technologies, Intravacc has transferred its technology world-wide for many vaccines, including polio, measles, DTP, Hib and influenza. Intravacc offers a wide range of expertise for independent vaccine development, from proof-of-concept to Phase I/II clinical studies for partners around the world, including universities, public health organizations, biotech and pharmaceutical companies.
The advertisement is available for download underneath.
Ernst & Young (EY) Strategy and Transactions, financial adviser to the Dutch State, at firstname.lastname@example.org.